Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 3
2015 1
2016 3
2017 3
2018 6
2019 7
2020 20
2021 14
2022 6
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: -N-methylmethylamine
Page 1
Structure-based discovery of opioid analgesics with reduced side effects.
Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, Levit A, Kling RC, Bernat V, Hübner H, Huang XP, Sassano MF, Giguère PM, Löber S, Da Duan, Scherrer G, Kobilka BK, Gmeiner P, Roth BL, Shoichet BK. Manglik A, et al. Nature. 2016 Sep 8;537(7619):185-190. doi: 10.1038/nature19112. Epub 2016 Aug 17. Nature. 2016. PMID: 27533032 Free PMC article.
Oliceridine: First Approval.
Markham A. Markham A. Drugs. 2020 Nov;80(16):1739-1744. doi: 10.1007/s40265-020-01414-9. Drugs. 2020. PMID: 33025536 Review.
The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects.
Urits I, Viswanath O, Orhurhu V, Gress K, Charipova K, Kaye AD, Ngo A. Urits I, et al. Curr Pain Headache Rep. 2019 Mar 18;23(5):31. doi: 10.1007/s11916-019-0773-1. Curr Pain Headache Rep. 2019. PMID: 30880365 Review.
Oliceridine is highlighted as a novel mu-opioid receptor agonist with selective activation of G protein and beta-arrestin signaling pathways. RECENT FINDINGS: Oliceridine (TRV130; [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4. …
Oliceridine is highlighted as a novel mu-opioid receptor agonist with selective activation of G protein and beta-arrestin signaling pathways …
Structure-activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.
Chen XT, Pitis P, Liu G, Yuan C, Gotchev D, Cowan CL, Rominger DH, Koblish M, Dewire SM, Crombie AL, Violin JD, Yamashita DS. Chen XT, et al. J Med Chem. 2013 Oct 24;56(20):8019-31. doi: 10.1021/jm4010829. Epub 2013 Oct 14. J Med Chem. 2013. PMID: 24063433
New opioid receptor modulators and agonists.
Kaye AD, Cornett EM, Patil SS, Gennuso SA, Colontonio MM, Latimer DR, Kaye AJ, Urman RD, Vadivelu N. Kaye AD, et al. Best Pract Res Clin Anaesthesiol. 2018 Jun;32(2):125-136. doi: 10.1016/j.bpa.2018.06.009. Epub 2018 Jul 2. Best Pract Res Clin Anaesthesiol. 2018. PMID: 30322454 Review.
New Drugs 2021, Part 2.
Hussar DA. Hussar DA. Nursing. 2021 Oct 1;51(10):18-29. doi: 10.1097/01.NURSE.0000791756.56705.dd. Nursing. 2021. PMID: 34580258
Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents.
Altarifi AA, David B, Muchhala KH, Blough BE, Akbarali H, Negus SS. Altarifi AA, et al. J Psychopharmacol. 2017 Jun;31(6):730-739. doi: 10.1177/0269881116689257. Epub 2017 Feb 1. J Psychopharmacol. 2017. PMID: 28142305 Free PMC article.
RATIONALE: TRV130 (oliceridine; N-[(3-methoxythiophen-2-yl)methyl]-2-[(9 R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine) is a novel mu opioid receptor (MOR) agonist that preferentially activates G-protein versus beta-arrestin signaling pathways …
RATIONALE: TRV130 (oliceridine; N-[(3-methoxythiophen-2-yl)methyl]-2-[(9 R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan- …
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine.
DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD. DeWire SM, et al. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17. doi: 10.1124/jpet.112.201616. Epub 2013 Jan 8. J Pharmacol Exp Ther. 2013. PMID: 23300227
Morphine pharmacology in beta-arrestin-2 knockout mice suggested that a ligand that promotes coupling of the mu-opioid receptor (MOR) to G proteins, but not beta-arrestins, would result in higher analgesic efficacy, less gastrointestinal dysfunction, and less respiratory suppress …
Morphine pharmacology in beta-arrestin-2 knockout mice suggested that a ligand that promotes coupling of the mu-opioid receptor (MOR) to G p …
69 results